← FDA DRUG APPROVALS

FDA NDA · NDA011557

TRILAFON

Sponsor: SCHERING

APPLICATION
NDA011557
TYPE
NDA
ORIGINAL APPROVAL
1958-12-12
LATEST ACTION
2001-09-17
ROUTE
ORAL
DOSAGE FORM
CONCENTRATE
MARKETING STATUS
Discontinued

Products

TRILAFONDiscontinued
PERPHENAZINE 16MG/5ML · CONCENTRATE · ORAL

Approval history

2001-09-17Labeling · Supplement 6AP
2001-09-17Labeling · Supplement 4AP
2001-09-17Labeling · Supplement 24 · standardAP
2001-09-17Labeling · Supplement 14AP
2001-09-17Labeling · Supplement 9AP
2001-09-17Labeling · Supplement 7AP
2001-09-17Labeling · Supplement 5AP
2001-09-17Labeling · Supplement 3AP
2001-09-17Labeling · Supplement 17AP
2001-09-17Labeling · Supplement 13AP
2001-09-17Labeling · Supplement 8AP
1982-03-29Labeling · Supplement 10AP
1958-12-12Type 3 - New Dosage Form · Original · standardAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industry →GMP discipline →FDA drug shortages →FDA enforcement & recalls →

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →